

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/001197

International filing date: 24 March 2005 (24.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0407587.5  
Filing date: 02 April 2004 (02.04.2004)

Date of receipt at the International Bureau: 18 May 2005 (18.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB05/1197



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subject the company to certain additional company law rules.

Signed

Dated 19 April 2005



# The Patent Office

Q5APR04 E886215-2 D01038  
P01/7700 0.00-0407587.5 NONE

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

02 APR 2004

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference LONDON P710579GB/DE/51743

2. Patent application number 0407587.5

(The Patent Office will fill in this part)

- 2 APR 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
The Nottingham Trent University  
Clifton Lane  
Nottingham  
NG11 8NS  
United Kingdom

7937030002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention Cancer Associated Antigens

5. Name of your agent (if you have one)  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)  
David ELSY  
WITHERS & ROGERS  
Goldings House  
2 Hays Lane  
London  
SE1 2HW

Patents ADP number (if you know it)

1776001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number


Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	----------------------------------------------	-------------------------------------

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	-------------------------------------

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

YES



Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 26

Claim(s) 4

Abstract -

Drawing (s) 3

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

*Winters & Rogers*  
Signature

Date 31 March 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

David Elsy

01926 336111

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500 505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.



## Cancer Associated Antigens

The invention relates to isolated nucleic acid sequences which are expressed in cancers, especially gastrointestinal, kidney and prostate cancers, to their protein products and to the use of the nucleic acid and protein products for the identification and treatment of cancers.

Cancers of the intestinal tract, such as gastric carcinomas and colorectal cancers, account for up to 15% of cancer-related deaths in the United States, and have low survival rates. Such cancers are often asymptomatic, the patient only becoming aware of them when the cancers have progressed too far to be successfully treated. There is therefore a need to identify new diagnostic tools and methods for treating such cancers.

The prostate gland is an accessory sex gland in males which is wrapped around the urethra as this tube leaves the bladder. The gland secretes an alkaline fluid during ejaculation. Cancer of the prostate gland is very serious and represents the second leading cause of death from cancer in men.

Two specific proteins are known to be made in very high concentrations in prostate cancer cells. These are prostatic acid phosphatase (PAP) and prostate specific antigen (PSA). These proteins have been characterised and have been used to follow response to therapy. However, it has been difficult to correlate the presence of these two proteins to the presence of cancer.

Accordingly, there is a need to identify new genes and proteins which are associated with the presence of prostate cancer.

Identification of immunogenic proteins in cancer is essential for the development of immunotherapeutic strategies where adoptive immunity is directed towards MHC Class I- and Class II-associated peptides (Mians, *et al.*, Cancer Immunology (2001), page 1). Many antigens are implicated in aetiology and progression of cancer, and are associated with epigenetic events. Pre-clinical and clinical studies infer that vaccination and targeting MHC-associated peptide antigens promotes tumour rejection (Ali S.A., *et al.*, J Immunol. (2002), Vol. 168(7), pages 3512-19 and Rees R.C., *et al.*, Immunol. Immunother (2002), Vol 51(1), pages 58-61).

The inventors have used a technique known as SEREX (Serological analysis of recombinant cDNA expression libraries) to identify genes which are over-expressed in cancer tissue. This technique was published by Sahin *et al* (PNAS (USA), 1995, Vol. 92,



pages 11810-11813). SEREX normally uses total RNA isolated from tumour biopsies from which poly(A)<sup>+</sup> RNA is then isolated. cDNA is then produced using an oligo (dT) primer. The cDNA fragments produced are then cloned into a suitable expression vector, such as a bacteriophage and cloned into a suitable host, such as *E.coli*. The clones produced are screened with high-titer IgG antibodies in autologous patient serum, to identify antigens associated with the tumour.

Several SEREX-defined antigens have provided attractive candidates for the construction of cancer vaccines, for example NY-ESO-1 from testis (Chen Y.T., *et al.* (1997), Vol. 4, page 1914; Stockert E., *et al.*, J. Exp. Med. (1998), Vol. 187, page 1349; Jager E., *et al.* PNAS (2000), Vol. 97, page 12198; and Jager E., *et al.*, PNAS (2000), Vol. 97, page 4760). Mutated p53 (Scanlan M.J., *et al.*, Int. J. Cancer (1998), Vol. 76, page 652), putative tumour suppressor ING 1 (Jager D. *et al.*, Cancer Res. (1999), Vol. 59, page 6416) and adhesion molecule galectin 9 (Tureci O., *et al.*, J. Biol. Chem. (1997), Vol. 272, page 6416), for example, have been detected by SEREX, showing that the analysis of autoantibodies can identify genes involved in cancer etiology and identify diagnostic markers or indicators of disease progression.

The inventors unexpectedly realised that some cancers express antigens that are also found in normal testes tissues. They therefore adapted the SEREX technique to screen a normal testicular tissue cDNA library against serum from pooled allogenic prostate cancer patients. This unexpectedly identified an antigen ("T128") which is highly expressed in malignant tissues, especially prostate and gastric cancers.

The testes cDNA library was screened using pooled allogeneic prostate cancer patients' sera. Seven reactive clones were purified, *in vivo* excised, and converted to plasmid forms. cDNA inserts were analysed using restriction mapping and cDNA sequencing.

Comparison to the Genbank non-redundant and expressed sequence tag (EST) databases revealed that these 7 clones represented 6 distinct genes, 5 previously unknown genes and 1 known gene. T128 was fully sequenced and is described here; the following results are consistent with T128 being a cancer-testis (CT) associated gene, the predicted protein of which it is believed will act as a new target antigen for immunotherapy.

T128 overlaps with a predicted, hypothetical coding sequence submitted to Genbank as accession number FLJ10330. The function and isolation of this was not referred to. This

hypothetical sequence was apparently found by Lee S.Y., *et al.* (PNAS, (2003), Vol. 100(5), pages 2651-2656) to be similar to an antigen found by serological analysis of cDNA expression libraries (clone NY-SAR-27). However, information published on this clone is limited and only seems to refer to a partial CDS. T128 is the full CDS. Furthermore, NY-SAR-27 is only mentioned in passing by Lee and was not developed further, presumably due to the limited reactivity observed (only 2 out of 39 sarcoma sera). This is in contrast with the full sequence now identified by the inventors and unexpectedly found to have considerably greater potential.

The invention provides an isolated mammalian nucleic acid molecule selected from the group consisting of:

- (a) Nucleic acid molecules encoding T128 polypeptide, as shown in Figure 1, a polypeptide at least 80% identical to T128, or a fragment thereof which is capable of cross-reacting with sera from patients with prostate cancer.
- (b) Nucleic acid molecules comprising the nucleotide sequence depicted in SEQ. ID. 1 between nucleic acid residues the start (ATG) and stop codon (TGA) of Figure 2 (i.e. 642 to 1688), also shown in SEQ. ID No. 3.
- (c) Nucleic acid molecules, the complementary strand of which specifically hybridises to a nucleic acid molecule in (a) or (b).
- (d) Nucleic acid molecules the sequence of which differs from the sequence of the nucleic acid molecule of (C) due to the degeneracy of the genetic code.

Preferably the nucleic acid molecule encodes T128. Preferably, the polypeptide is expressed in higher than normal concentrations in gastric, kidney and/or prostate cancer tissue, compared to one or more of normal lung, liver, kidney, heart, brain, trachea, and/or prostate.

Preferably the polypeptide is expressed in higher concentrations of normal testicular tissue compared with the normal tissues listed above.

Preferably the nucleic acid molecule encodes a polypeptide which is capable of acting as a transcription factor. That is, it is capable of binding a DNA molecule and regulating the transcription of a region of that DNA molecule by an RNA polymerase. Most preferably

the polypeptide has nuclear localisation. Initial analysis of the data shows that this is a property of the polypeptide.

The sequence especially has one or more of the following features:

Chromosomal localization Ip13.3

N-glycosylation site at position 264-267

cAMP-phosphorylation sites 60-63, 118-121, 130-133, 219-222, 226-229, 301-304, 327-330.

PKC phosphorylation sites at positions 65-67, 71-73, 75-77, 222-224, 259-261, 270-272, 288-290, 300-302, 310-312, 322-324.

Casein kinase 2 phosphorylation sites at positions 2-5, 12-15, 92-95, 197-200, 222-225.

Tyrosine phosphorylation sites at position 167-173.

Amidation sites at positions 165-168, 247-250.

Arginine rich region 56-254.

Lysine rich region 204-322.

Serine rich region 229-322.

Nucleic acid molecules having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homology to the nucleic acid molecules are also provided. Preferably these express proteins which are expressed in higher concentrations in cancerous tissue than the equivalent normal tissue. That is they are higher in e.g. prostate cancer or gastric cancers than normal, non-cancerous, prostate, kidney or normal non-cancerous gastric tissue. The proteins are preferably expressed in higher concentrations in gastric, kidney and/or prostate cancer tissue, more preferably and normal testes than in e.g. one or more of other, normal tissues such as normal lung, liver, heart, brain, trachea, and/or prostate. Preferably this is at least 2, most preferably at least 5 times higher concentrations than normal tissue.

The nucleic acid molecules of the invention may be DNA, cDNA or RNA. In RNA molecules "T" (Thymine) residues may be replaced by "U" (Uridine) residues.

Preferably, the isolated mammalian nucleic acid molecule is an isolated human nucleic acid molecule.

The invention further provides nucleic acid molecules comprising at least 15 nucleotides capable of specifically hybridising to a sequence included within the sequence of a nucleic

acid molecule according to the first aspect of the invention. The hybridising nucleic acid molecule may either be DNA or RNA. Preferably the molecule is at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, homologous to the nucleic acid molecule according to the first aspect of the invention. This may be determined by techniques known in the art.

The term "specifically hybridising" is intended to mean that the nucleic acid molecule can hybridise to nucleic acid molecules according to the invention under conditions of high stringency. Typical conditions for high stringency include 0.1 x SET, 0.1% SDS at 68°C for 20 minutes.

The invention also encompasses variant nucleic acid molecules such as DNAs and cDNAs which differ from the sequences identified above, but encode the same amino acid sequences as the isolated mammalian nucleic acid molecules, by virtue of redundancy in the genetic code.

	U		C		A		G	
U	UUU } Phe UUC } UUA } Leu UUG }		UCU } UCC } Ser UCA } UCG }		UAU } Tyr UAC } UAA* Stop UAG* Stop		UGU } Cys UGC } UGA* Stop UGG Trp	U C A G
C	CUU } CUC } Leu CUA } CUG }		CCU } CCC } Pro CCA } CCG }		CAU } His CAC } CAA } Gln CAG }		CGU } CGC } Arg CGA } CGG }	U C A G
A	AUU } AUC } Ile AUA } AUG** Met		ACU } ACC } Thr ACA } ACG }		AAU } Asn AAC } AAA } Lys AAG }		AGU } Ser AGC } AGA } Arg AGG }	U C A G
G	GUU } GUC } Val GUA } GUG**		GCU } GCC } Ala GCA } GCG }		GAU } Asp GAC } GAA } Glu GAG }		GGU } GGC } Gly GGA } GGG }	U C A G

\* Chain-terminating, or "nonsense" codons.

\*\* Also used to specify the initiator formyl-Met-tRNA<sup>Met</sup>. The Val triplet GUG is therefore "ambiguous" in that it codes both valine and methionine.

### The genetic code showing mRNA triplets and the amino acids for which they code

The invention also includes within its scope vectors comprising a nucleic acid according to the invention. Such vectors include bacteriophages, phagemids, cosmids and plasmids. Preferably the vectors comprise suitable regulatory sequences, such as promoters and termination sequences which enable the nucleic acid to be expressed upon insertion into a suitable host. Accordingly, the invention also includes hosts comprising such a vector. Preferably the host is *E. coli*.

A second aspect of the invention provides an isolated polypeptide obtainable from a nucleic acid sequence according to the invention. As indicated above, the genetic code for translating a nucleic acid sequence into an amino acid sequence is well known.

Preferably the sequence comprises the sequence shown in Figure 1.

The invention further provides polypeptide analogues, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity of location of one or more amino acid residues (deletion analogues containing less than all of the residues specified for the protein, substitution analogues wherein one or more residues specified are replaced by other residues in addition analogues wherein one or more amino acid residues are added to a terminal or medial portion of the polypeptides) and which share some or all properties of the naturally-occurring forms. Preferably such polypeptides comprise between 1 and 20, preferably 1 and 10 amino acid deletions or substitutions.

Preferably the polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences of the invention. This can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

Preferably the polypeptides of the invention do not contain one or more amino acid residues from upstream of the sequence shown in Figure 1 from the sequence shown as FLJ10330. That is one or more amino acids before MTIGEMLR... etc. found in sequence FLJ10330.

The nucleic acids and polypeptide of the invention are preferably identifiable using the SEREX method. However, alternative methods, known in the art, may be used to identify nucleic acids and polypeptides of the invention. These include differential display PCR (DD-PCR), representational difference analysis (RDA) and suppression subtracted hybridisation (SSH).

The nucleic acid molecules encoding T128 according to the invention and the polypeptides which they encode are detectable by SEREX (discussed below). The technique uses serum antibodies from cancer patients to identify the molecules. It is therefore the case that the gene products identified by SEREX are able to evoke an immune response in a patient and may be considered as antigens suitable for potentiating further immune reactivity if used as a vaccine.

The third aspect of the invention provides the use of nucleic acids or polypeptides according to the invention, to detect or monitor cancers, preferably gastro-intestinal cancers, such as gastric cancer or prostate cancer.

The use of a nucleic acid molecule hybridisable under high stringency conditions, a nucleic acid according to the first aspect of the invention to detect or monitor cancers, e.g. gastro-intestinal cancers, such as gastric cancer or colorectal cancer, or prostate cancer, is also encompassed. Such molecules may be used as probes, e.g. using PCR.

The expression of genes, and detection of their polypeptide products may be used to monitor disease progression during therapy or as a prognostic indicator of the initial disease status of the patient.

There are a number of techniques which may be used to detect the presence of a gene, including the use of Northern blot and reverse transcription polymerase chain reaction (RT-PCR) which may be used on tissue or whole blood samples to detect the presence of cancer associated genes. For polypeptide sequences *in-situ* staining techniques or enzyme linked ELISA assays or radio-immune assays may be used. RT-PCR based techniques would result in the amplification of messenger RNA of the gene of interest (Sambrook, Fritsch and Maniatis, Molecular Cloning, A Laboratory Manual, 2<sup>nd</sup> Edition). ELISA based assays necessitate the use of antibodies raised against the protein or peptide sequence and may be used for the detection of antigen in tissue or serum samples (McIntyre C.A., Rees R.C. *et. al.*, Europ. J. Cancer 28, 58-631 (1990)). In-situ detection of antigen in tissue sections also rely on the use of antibodies, for example, immuno peroxidase staining or alkaline phosphatase staining (Gaepel, J.R., Rees, R.C. *et. al.*, Brit. J. Cancer 64, 880-883 (1991)) to demonstrate expression. Similarly radio-immune assays may be developed whereby antibody conjugated to a radioactive isotope such as I<sup>125</sup> is used to detect antigen in the blood.

Blood or tissue samples may be assayed for elevated concentrations of the nucleic acid molecules or polypeptides.

Preferably elevated levels of the molecules in tissues that are not normal testes is indicative of the presence of cancerous tissues.

Methods of producing antibodies which are specific to the polypeptides of the invention, for example, by the method of Kohler & Milstein to produce monoclonal antibodies, are well known. A further aspect of the invention provides an antibody, e.g. a monoclonal antibody, which specifically binds to a polypeptide according to the invention.

Kits for detecting or monitoring cancer, such as gastro-intestinal cancers, including gastric cancer and/or colorectal cancer, or prostate cancer, using polypeptides, nucleic acids or antibodies according to the invention are also provided. Such kits may additionally contain instructions and reagents to carry out the detection or monitoring.

The fourth aspect of the invention provides for the use of nucleic acid molecules according to the first aspect of the invention or polypeptide molecules according to the second aspect of the invention in the prophylaxis or treatment of cancer, or pharmaceutically effective fragments thereof. By pharmaceutically effective fragment, the inventors mean a fragment of the molecule which still retains the ability to be a prophylactant or to treat cancer. The cancer may be a gastro-intestinal cancer, such as gastric cancer or colorectal cancer.

The molecules are preferably administered in a pharmaceutically amount. Preferably the dose is between 1  $\mu\text{g/kg}$ . to 10  $\text{mg/kg}$ .

The nucleic acid molecules may be used to form DNA-based vaccines. From the published literature it is apparent that the development of protein, peptide and DNA based vaccines can promote anti-tumour immune responses. In pre-clinical studies, such vaccines effectively induce a delayed type hypersensitivity response (DTH), cytotoxic T-lymphocyte activity (CTL) effective in causing the destruction (death by lysis or apoptosis) of the cancer cell and the induction of protective or therapeutic immunity. In clinical trials peptide-based vaccines have been shown to promote these immune responses in patients and in some instances cause the regression of secondary malignant disease. Antigens expressed in prostate cancer (or other types of cancers) but not in normal tissue (or only weakly expressed in normal tissue compared to cancer tissue) will allow us to assess their efficacy in the treatment of cancer by immunotherapy. Polypeptides derived from the tumour antigen may be administered with or without immunological adjuvant to promote T-cell responses and induce prophylactic and therapeutic immunity. DNA-based vaccines preferably consist of part or all of the genetic sequence of the tumour antigen inserted into



an appropriate expression vector which when injected (for example via the intramuscular, subcutaneous or intradermal route) cause the production of protein and subsequently activate the immune system. An alternative approach to therapy is to use antigen presenting cells (for example, dendritic cells, DC's) either mixed with or pulsed with protein or peptides from the tumour antigen, or transfect DC's with the expression plasmid (preferably inserted into a viral vector which would infect cells and deliver the gene into the cell) allowing the expression of protein and the presentation of appropriate peptide sequences to T-lymphocytes or adaptive cellular therapy using, *e.g.*, T-cells responsive to T128 peptides or T128 protein.. A DNA based vaccine is demonstrated in, for example, Thompson S.A., *et al.* (J. Immunol. (1998), Vol. 160, pages 1717-1723).

Accordingly, the invention provides a nucleic acid molecule according to the invention in combination with a pharmaceutically-acceptable carrier.

Such polypeptides may be bound to a carrier molecule such as tetanus toxoid to make the polypeptide immunogenic. Such constructs are also within the scope of the invention.

A further aspect of the invention provides a method of prophylaxis or treatment of a cancer such as a gastro-intestinal cancer, or prostate cancer, comprising the administration to a patient of a nucleic acid molecule according to the invention.

The polypeptide molecules according to the invention may be used to produce vaccines to vaccinate against a cancer, such as a gastro-intestinal cancer or prostate cancer.

Accordingly, the invention provides a polypeptide according to the invention in combination with a pharmaceutically acceptable carrier.

The invention further provides use of a polypeptide according to the invention in a prophylaxis or treatment of a cancer such as a gastro-intestinal cancer, kidney cancer or prostate cancer.

Methods of prophylaxis or treating a cancer, such as a gastro-intestinal cancer, or prostate cancer, by administering a protein or peptide according to the invention to a patient, are also provided.

Vaccines comprising nucleic acid and/or polypeptides according to the invention are also provided. The polypeptide may be attached to another carrier peptide such as tetanus toxoid to increase the immunogenicity of the polypeptide.

The polypeptides of the invention may be used to raise antibodies. In order to produce antibodies to tumour-associated antigens procedures may be used to produce polyclonal antiserum (by injecting protein or peptide material into a suitable host) or monoclonal antibodies (raised using hybridoma technology). In addition PHAGE display antibodies may be produced, this offers an alternative procedure to conventional hybridoma methodology. Having raised antibodies which may be of value in detecting tumour antigen in tissues or cells isolated from tissue or blood, their usefulness as therapeutic reagents could be assessed. Antibodies identified for their specific reactivity with tumour antigen may be conjugated either to drugs or to radioisotopes. Upon injection it is anticipated that these antibodies localise at the site of tumour and promote the death of tumour cells through the release of drugs or the conversion of pro-drug to an active metabolite. Alternatively a lethal effect may be delivered by the use of antibodies conjugated to radioisotopes. In the detection of secondary/residual disease, antibody tagged with radioisotope could be used, allowing tumour to be localised and monitored during the course of therapy. Unconjugated antibodies can also be useful in influencing cancer cell growth. For example, the binding of certain antibodies to cell-surface receptors on cancer cells may initiate cell death by, e.g., apoptosis. Therefore the antibodies of this invention could be therapeutically useful in a non-conjugated form.

The term "antibody" includes intact molecules as well as fragments such as  $F_a$ ,  $F(ab')_2$  and  $F_v$ .

The invention accordingly provides a method of treating a cancer such as gastro-intestinal, kidney cancer, or prostate cancer, by the use of one or more antibodies raised against a polypeptide of the invention.

The cancer-associated proteins identified may form targets for therapy.

The invention also provides nucleic acid probes capable of binding sequences of the invention under high stringency conditions. These may have sequences complementary to the sequences of the invention and may be used to detect mutations identified by the inventors. Such probes may be labeled by techniques known in the art, e.g. with radioactive or fluorescent labels.

Preferably the cancer which is detected, assayed for, monitored, treated or targeted for prophylaxis, is a gastric cancer or prostate cancer.

The invention will now be described by reference to the following figure and examples:

**Figure 1**

T128 polypeptide amino acid sequence.

**Figure 2**

Nucleic acid sequence encoding T128. Start codon (ATG) and stop codon (TGA) are underlined. The nucleic acid sequence encoding T128 is also provided in SEQ. ID No. 2, the corresponding open reading frame is provided in SEQ. ID No. 3 and the 25 nucleotide fragment given in bold is provided in SEQ. ID No. 4.

**Figure 3**

Tissue expression analysis of T128 transcripts analysed by RT-Q-PCR. To calculate an arbitrary level of expression of T128 using RT-Q-PCR a standard curve was generated using serial dilutions of testis cDNA as template and assigning the dilutions arbitrary concentration values. T128 gene specific primers were then used in the RT-Q-PCR reactions to generate gene specific product. A panel of normal and malignant samples was run in parallel to the standard curve and arbitrary quantities of T128 expression were calculated from the standard curve. The same cDNA samples were tested for GAPDH, an internal control. These expression levels were then normalised to GAPDH by dividing the quantity of T128 gene specific product by the quantity of GAPDH in the same sample. T128 transcripts are over expressed in malignant tissues (gastric and kidney) ( $p < 0.05$ ) and normal testes ( $p < 0.01$ ) when compared to normal tissues (lung, liver, heart, brain, trachea, kidney, adrenal gland, endometrium, colon, breast, PBMC, tonsil, small intestine, vagina, muscle, placenta and ovary).

**Figure 4**

Expression of T128 analysed by RT-PCR. Varying levels of T128 expression are also found in selected BPH samples. The same cDNA samples were tested for GAPDH, as an internal control.

Technique used to identify genes encoding tumour antigens (SEREX technique)

The technique for the expression of cDNA libraries from human testes is described and was performed according to published methodology (Sahin *et. al.* Proc Natl. Acad. Sci. 92, 11810-11813, 1995).

SEREX has been used to analyze gene expression in tumour tissues from human melanoma, renal cell cancer, astrocytoma, oesophageal squamous cell carcinoma, colon cancer, lung cancer and Hodgkin's disease. Sequence analysis revealed that several different antigens, including HOM-MEL-40, HOM-HD-397, HOM-RCC-1.14, NY-ESO-1, NY-LU-12, NY-CO-13 and MAGE genes, were expressed in these malignancies, demonstrating that several human tumour types express multiple antigens capable of eliciting an immune response in the autologous host. This represents an alternative and more efficient approach to identify tumour markers, and offers distinct advantages over previously used techniques:

- 1) the use of fresh tumour specimens to produce the cDNA libraries obviates the need to culture tumour cells *in vitro* and therefore circumvents artefacts, such as loss or neo-antigen expression and genetic and phenotypic diversity generated by extended culture;
- 2) the analysis is restricted to antigen-encoding genes expressed by the tumour *in vivo*;
- 3) using cDNA expression cloning, the serological analysis (in contrast to autologous typing) is not restricted to cell surface antigens, but covers a more extensive repertoire of cancer-associated proteins (cytosolic, nuclear, membrane, etc.);
- 4) in contrast to techniques using monoclonal antibodies, SEREX uses poly-specific sera to scrutinise single antigens that are highly enriched in lytic bacterial plaques allowing the efficient molecular identification of antigens following sequencing of the cDNA. Subsequently the tissue-expression spectrum of the antigen can be determined by the analysis of the mRNA expression patterns using, for example, northern blotting and reverse transcription-PCR (RT-PCR), on fresh normal and malignant (autologous and allogeneic) tissues. Likewise, the prevalence of antibody in cohorts of cancer patients and normal controls can be determined.

The T128 sequence can be isolated by the polymerase chain reaction using the following pair of primers:

T128 Primer 1: GAGAGAGCGATCAAGAGAAAGG (SEQ ID No. 5)  
 T128 Primer 2: ATCTCTGTGCCGCTATCAT (SEQ ID No. 6)

under the following reaction conditions:

Temperature (°C)	Time (minutes)	Cycles	Comment
95	15	1	Denaturation
95	0.75	33	Denaturation
58	0.75		Annealing
72	1.5		Extension
95	1	1	Denaturation

The terms 'denaturation', 'annealing' and 'extension' are well-known and understood to the person skilled in the art of PCR and the reader is directed to 'Figure 10.1 in Principles of Gene Manipulation. An Introduction to Genetic Engineering (5th Edition, 1994). R.W. Old and S.B. Primrose (Publisher: Blackwell Science).

#### **Extraction of nucleic acid from tissue**

A prokaryotically expressed cDNA library can be constructed by isolating 10µg of total RNA from normal testes tissues, treating the total RNA with Calf Intestinal Phosphatase to remove 5'-phosphates from un-capped RNAs, removing the cap structure from full-length mRNA by Tobacco Acid Pyrophosphatase (TAP) and ligating RNA adapters to mRNA molecules containing 5'phosphate. The actual library used was a commercially available λTriplEx2™ Human testes large-insert cDNA library (Product 634220, Clontech, Palo Alto, CA, USA).

#### **Serological Analysis of Recombinant cDNA Expression Libraries (SEREX)**

The SEREX approach allows an unbiased search for an antibody response and the direct molecular definition of immunogenic tumour proteins based on their reactivity with allogeneic patient sera. In this approach, a prokaryotically expressed cDNA library constructed from normal human testes was immunoscreened with absorbed and diluted patients' sera for the detection of tumour antigens that have elicited a high-titer immunoglobulin (Ig) G humoral response. Such a humoral response implies T-cell recognition of the detected antigens by helper T cells. Thus, even though the antigens are initially identified by antibodies, the method reveals tumour products that can then be analysed in the context of cell-mediated immunity. The SEREX approach can then be

modified and used to determine the reactivity of identified antigens with panels of human sera including prostate cancer patient sera and normal donor sera.

In this case, the SEREX approach was modified by pooling allogeneic sera from four prostate cancer patients to screen a normal testes cDNA library, rather than a cancer cDNA library, to identify cancer-testes (C-T) antigens.

Inserts were sequenced on a ABI Prism semi-automated sequencer using T7 primers specific for the vector.

### **Rapid Amplification of the cDNA ends (RACE)**

Sequencing of the clones identified following immunoscreening allows only the cDNA insert sequence to be in attained full. The complete 5'- and 3'- ends of the sequence can then be obtained using a procedure termed rapid amplification of cDNA ends (RACE). The SMART™ RACE cDNA amplification kit (BD Biosciences, Clontech, Palo Alto, CA, USA) used provides a novel method for performing both 5'- and 3'-RACE. In brief, first-strand cDNA synthesis is performed on high quality testes RNA expressing the gene of interest. The cDNA for 5'-RACE-ready cDNA is synthesised using a modified lock-docking oligo (dT) primer and the SMART II oligo. The 3'-RACE-ready cDNA is synthesised using a traditional reverse transcription procedure but with a special oligo (dT) primer. This primer also has a portion of the SMART sequence at its 5' end. By incorporating the SMART sequence into both the 5'- and 3'-RACE-ready cDNA populations, both PCR reactions can be primed using the universal primer mix (UPM) A, that recognises the SMART sequence, in conjunction with distinct gene-specific primers designed to amplify either in the 5' or 3' direction.

### **Setting up 5' and 3' RACE PCR reactions**

<b>Component</b>	<b>5'-RACE sample</b>	<b>3'-RACE sample</b>
RACE-Ready cDNA	2.5 µl	2.5 µl
UPM (10X)	5 µl	5 µl
5' RACE gene specific primer (SEQ ID No 7) TCTTCCTTGACTGCCACTTCGACTTCGT	1 µl	
3' RACE gene specific primer (SEQ ID No 8) CGGCCAAGATCCCGAAGTATTGACC		1 µl
Master Mix	41.5 µl	41.5 µl

A primary PCR was carried out using the 3' RACE gene specific primers under the following reaction conditions:

Temperature (°C)	Time (minutes)	Cycles	Comment
94	0.5	5	Denaturation
72	2		Extension
94	0.5	35	Denaturation
70	0.5		Annealing
72	2		Extension

Subsequently the reaction product from the primary 3' RACE PCR was used as template nucleic acid in 3' RACE nested PCR using 3' RACE nested PCR primers under the following reaction conditions:

Temperature (°C)	Time (minutes)	Cycles	Comment
94	0.5	4	Denaturation
70	0.5		Annealing
72	3		Extension

3' RACE gene specific nested primer: ACGAAGTCGAAGTGGCAGTCAAGGAAGA (SEQ ID No 9).

A primary PCR was carried out using the 5' RACE gene specific primers under the following reaction conditions:

Temperature (°C)	Time (minutes)	Cycles	Comment
94	0.5	5	Denaturation
72	2		Extension
94	0.5	5	Denaturation
70	0.5		Annealing
72	2		Extension
94	0.5	30	Denaturation
68	0.5		Annealing
72	2		Extension

An equivalent 'nested' PCR reaction was not undertaken for the 5' RACE gene since the primary 5' RACE PCR generated a sufficiently pure product and sequencing of this product demonstrated that the correct product had been generated.

The reactivity of promising positive clones against patient and normal donor serum was determined by immunoscreening the clones against and allogeneic panel of 10 prostate

cancer patients' sera and 10 healthy donor patients' sera. The methodology used was the same as the SEREX methodology (described above) with the following modifications: The positive clone (T128) and a negative clone (blue phage) were plated out on a small LB agar plate at a ratio of 1:2 to give a titre of approximately 600 pfu/plate. The steps for detection of false positives, subcloning and re-testing were not necessary. Following expression overnight, plaque expression and transferral of the plaques to nitrocellulose membranes, the nitrocellulose membranes were incubated with the individual serum and colour developed as described previously. The results would then be recorded simply as being positive (plaques visible) or negative (no plaques visible).

### **Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (RT-Q-PCR)**

RT-Q-PCR was used to determine the tissue specificity of T128 expression of SEREX-defined genes in various tissues and cell lines. The indicator dye used was SYBR green.

RT-Q-PCR quantitates the initial amount of template most specifically, sensitively and reproducibly, and is a preferable alternative to semi-quantitative RT-PCR which detects the amount of final amplified product. Real time PCR monitors the fluorescence emitted during the reaction as an indicator of amplicon production during each PCR cycle as opposed to the endpoint detection by conventional PCR methods. The quantitative detection of the amplicon can be measured using a DNA-binding agent called SYBR green (Molecular Probes Inc., Eugene, OR, USA). SYBR green is a non-sequence specific fluorescent intercalating agent that only binds to double stranded DNA within the minor groove.

The Mx4000 apparatus measures the fluorescence of each sample at the end of the annealing step, and at the end of each cycle when creating the dissociation curve. After the RT-PCR reaction, the software program plots linear values of fluorescence (dRn) against cycle number. After background adjustment, the Ct value, which is defined as the number of cycles at which the reaction crosses a threshold value, i.e. the fluorescence due to the RT-PCR product exceeds the background level, is calculated for each sample by the software. The software produces a standard curve by measuring the Ct value of each standard and plotting it against the approximate concentrations for the corresponding standard dilution. The expression level of the unknown genes in a given RNA sample are then normalised to the housekeeping gene GAPDH. The normalised expression of each



gene is calculated by dividing the Ct value for the unknown gene in a sample by the Ct value for GAPDH in the same sample. Thus, a sample with high level expression of a gene will have a lower Ct value because the gene is more abundant, hence it takes less cycles for the fluorescence to exceed that of background levels. Therefore, when calculating the normalised expression for that gene the Ct value would be lower than a gene that is less abundant. This should be remembered when observing the normalised expression graphs because the lower the Ct value the more abundant the gene is in the sample. Derivation of this fraction is independent of RNA sample concentration, eliminating the requirement to measure RNA concentration accurately.

The RT-Q-PCR reactions were performed in the Mx4000 QPCR system (Stratagene, UK) using SYBR green fluorescent dye (Yin, J.L. *et al.*, 2001. *Immuno. Cell Biol.* 79(3):213-21). RNA samples were DNase treated in order to remove genomic DNA following standard protocols. Thermocycling for each reaction was done in a final volume of 25 µl containing 1 µl of template (1:10 diluted), or standard, 12.5 µl SYBR green master mix (Qiagen, UK) containing Hot Start®Taq DNA polymerase, reaction buffer, ROX reference dye, SYBR green dye, magnesium chloride and deoxynucleotides, and pre-optimised amounts of gene-specific forward and reverse primers. This was then made up to 25 µl with Qiagen water. In each experiment a minimum of 8 no-template controls should be included to ensure no contamination has occurred and also to indicate the degree of amplification due to primer dimers. Also included were 4 RT-negative (no reverse transcription) samples to ensure that genomic DNA had been completely removed following DNase treatment.

Gene specific primer sequences SEQ ID No 8 and 9 (see above) were used in both conventional and real time PCR.

### ***In silico* analysis of T128**

The amino acid sequence of T128 was analysed using search programs including PROSITE (accessible at [www.expasy.ch/prosite/](http://www.expasy.ch/prosite/)), PSORT (accessible at <http://psort.nibb.ac.jp>) and Pfam (accessible at <http://www.sanger.ac.uk/cgi-bin/Pfam/nph-search.cgi>). These identified:

Chromosomal localization Ip13.3

N-glycosylation site at position 264-267

cAMP-phosphorylation sites 60-63, 118-121, 130-133, 219-222, 226-229, 301-304, 327-330.

PKC phosphorylation sites at positions 65-67, 71-73, 75-77, 222-224, 259-261, 270-272, 288-290, 300-302, 310-312, 322-324.

Casein kinase 2 phosphorylation sites at positions 2-5, 12-15, 92-95, 197-200, 222-225.

Tyrosine phosphorylation sites at position 167-173.

Amidation sites at positions 165-168, 247-250.

Arginine rich region 56-254.

Lysine rich region 204-322.

Serine rich region 229-322.

## RESULTS

### Tissue specificity

The results of tissue specificity studies are shown in Figures 3 and 4. The Table shows the reactivity of patients sera with T128.

Tables of results to show the immunoreactivity of 10 individual prostate cancer patients' sera and 10 individual normal patients' sera with the 6 positive clones identified following immunoscreening:

#### Immunoreactivity of prostate cancer patients' serum

	Immunoreactivity Observed with Serum									
Clone	Pr27	Pr29	Pr32	Pr33	Pr34	Pr36	Pr37	Pr38	Pr39	Pr48
128	+	-	+	+	+	-	+	+	-	-

#### Immunoreactivity of normal patients' serum

	Immunoreactivity Observed with Serum									
Clone	Nor1	Nor2	Nor3	Nor5	Nor12	Nor13	Nor14	Nor19	Nor20	Nor21
128	-	-	-	+	-	-	+	+	-	-

The antigen is testes specific in normal tissues, but is highly expressed in cancerous tissues.

### Sequence

T128 was sequenced and the homology of sequence was compared with homologous sequences on Genbank. This showed some overlap with a hypothetical protein, FLJ10330.

The sequence of T128 is shown in Figures 1 and 2.

## CONCLUSIONS

T128 is an antigen that is testes specific in normal tissue. Cancerous tissue has high levels of expression of this antigen from cancers derived from tissues other than testes. Prostate, kidney and gastric cancers have high levels of the antigen expressed, making it a good marker for cancer and a target as a therapeutic agent. The immunogenic activity of this antigen is demonstrated by the identification of antibodies in cancer sufferers which assisted in identifying this antigen via the use of the SEREX method.

## SEQUENCE LISTING

<110> The Nottingham Trent University

<120> T128 Testes Antigen

<130> P710579GB

<160> 4

<170> PatentIn version 3.2

<210> 1

<211> 349

<212> PRT

<213> Homo sapiens

<400> 1

Met Thr Ile Gly Glu Met Leu Arg Ser Phe Leu Thr Lys Leu Glu Trp  
1           5           10           15

Phe Ser Thr Leu Phe Pro Arg Ile Pro Val Pro Val Gln Lys Asn Ile  
20           25           30

Asp Gln Gln Ile Lys Thr Arg Pro Arg Lys Ile Lys Lys Asp Gly Lys  
35           40           45

Glu Gly Ala Glu Glu Ile Asp Arg His Val Glu Arg Arg Arg Ser Arg  
50           55           60

Ser Pro Arg Arg Ser Leu Ser Pro Arg Arg Ser Pro Arg Arg Ser Arg  
65           70           75           80

Ser Arg Ser His His Arg Glu Gly His Gly Ser Ser Ser Phe Asp Arg  
85           90           95

Glu Leu Glu Arg Glu Lys Glu Arg Gln Arg Leu Glu Arg Glu Ala Lys  
100           105           110

Glu Arg Glu Lys Glu Arg Arg Arg Ser Arg Ser Ile Asp Arg Gly Leu  
115           120           125

Glu Arg Arg Arg Ser Arg Ser Arg Glu Arg His Arg Ser Arg Ser Arg  
130 135 140

Ser Arg Asp Arg Lys Gly Asp Arg Arg Asp Arg Asp Arg Glu Arg Glu  
145 150 155 160

Lys Glu Asn Glu Arg Gly Arg Arg Arg Asp Arg Asp Tyr Asp Lys Glu  
165 170 175

Arg Gly Asn Glu Arg Glu Lys Glu Arg Glu Arg Ser Arg Glu Arg Ser  
180 185 190

Lys Glu Gln Arg Ser Arg Gly Glu Val Glu Glu Lys Lys His Lys Glu  
195 200 205

Asp Lys Asp Asp Arg Arg His Arg Asp Asp Lys Arg Asp Ser Lys Lys  
210 215 220

Glu Lys Lys His Ser Arg Ser Arg Ser Arg Glu Arg Lys His Arg Ser  
225 230 235 240

Arg Ser Arg Ser Arg Asn Ala Gly Lys Arg Ser Arg Ser Arg Ser Lys  
245 250 255

Glu Lys Ser Ser Lys His Lys Asn Glu Ser Lys Glu Lys Ser Asn Lys  
260 265 270

Arg Ser Arg Ser Gly Ser Gln Gly Arg Thr Asp Ser Val Glu Lys Ser  
275 280 285

Lys Lys Arg Glu His Ser Pro Ser Lys Glu Lys Ser Arg Lys Arg Ser  
290 295 300

Arg Ser Lys Glu Arg Ser His Lys Arg Asp His Ser Asp Ser Lys Asp  
305 310 315 320

Gln Ser Asp Lys His Asp Arg Arg Arg Ser Gln Ser Ile Glu Gln Glu  
 325 330 335

Ser Gln Glu Lys Gln His Lys Asn Lys Asp Glu Thr Val  
 340 345

<210> 2  
 <211> 2062  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (2037)..(2037)  
 <223> n is a, c, g, or t

<400> 2  
 acgcgggggtt tccaattatt tgttcattta tttattttct acataactaa attagaaacc 60  
 tcactgcttc atggcagttg gtttgctatt gcttcagtt ttattagggc ttcattttat 120  
 attagagctg ttaaagata accttagac aggaattatc taaagtagac attttatatt 180  
 agagctgtta aaagataacc ttagacagg aattatctaa agtagatcat atgtagctag 240  
 gttatgggtgc aagggtgatg atgtgtgcaa atatgtccac agaaataaat acatagtagg 300  
 tatgtggaat gttaaattta gtcaatcgtt ccgcatagtt tagaaatgta agggggctttt 360  
 tcatattgtt aactgagtga gatcagttcc ctttatgcct gtgaggctgc agggtttgtt 420  
 ctcaattgca tgcacacact aagcccaaatt atttctgttc attcattgtc agatcaggat 480  
 atgaaaataa aatttttctg ttagtttttt ttgtattgag attccaaaga tggtaatatt 540  
 ttataatat tcatgtatat atggaaatac ttttttgac ggctagggta tcttttgtgt 600  
 ttctgtagga cctagatgtg aaggctgggtg gaggtgtgt aatgaccatt ggagaaatgc 660  
 tacgatcttt tctcacaaaa ctggagtggt tttctacctt gttccaaga attccagttc 720  
 cagttcaaaa gaatattgat caacagatta aaacccgacc tagaaaaatc aagaaagatg 780  
 ggaaggaagg tgctgaggaa atagacagac atgttgaacg cagacgttca aggtctccaa 840

ggagatctct gaggccacgg aggtcccaa gaaggtcaag aagtagaagt catcatcggg 900  
 agggccatgg gtcttctagt ttgacagag aattagaaag agagaaagaa cgccagcgac 960  
 tagagcgtga agccaaagaa agggagaaag aacggcgaag atcccgaagt attgaccggg 1020  
 ggtagaacg caggcgcagc agaagtaggg aaaggcatag aagtcgcagt cgaagtcgtg 1080  
 ataggaaagg gtagagaagg gacagggatc gagaagaga gaaagaaaat gagagaggta 1140  
 gaagacgaga tcgtgactat gataaggaaa gaggaatga acgagaaaaa gagagagagc 1200  
 gatcaagaga aaggtccaag gaacagagaa gtaggggaga ggtagaagag aagaaacata 1260  
 aagaagacaa agatgatagg cggcacagag atgacaaaag agattccaag aaagagaaaa 1320  
 aacacagtag aagcagaagc agagaaagga aacacagaag taggagtcga agtagaaatg 1380  
 cagggaaacg aagtagaagt agaagcaaag agaaatcaag taaacataaa aatgaaagta 1440  
 aagaaaaatc aaataaacga agtcgaagtg gcagtcaagg aagaactgac agtgttgaaa 1500  
 aatcaaaaaa acgggaacat agtcccagca aagaaaaatc tagaaagcgt agtagaagca 1560  
 aagaacgttc ccacaaacga gatcacagtg atagtaagga ccagtcagac aaacatgatc 1620  
 gtccaaggag ccaaagtata gaacaagaga gccaaagaaa acagcataaa aacaaagatg 1680  
 agactgtgtg aaaatatatt gtaaaagtgg atcacattga atcctataaa tgattaaatc 1740  
 tgctttttc cccacgttg agattgtgca gtagttcgca ctctcaagc tctccctgta 1800  
 ggctgcattt tcatttctc ttctgttag ggaagtcct ttgtaattcc atttattgca 1860  
 ttggtgtttt caccaattg ttaagttga tacatgatgc acagattgtt cttgcatttt 1920  
 tattgtttgt tttgaaatg tacagtctgt acatatgtcc tgaaaatgtt ttaattcctt 1980  
 tggcatggtt accatgttgg ttaaatttgt ataaggcaat aaactgccac taatcnaaa 2040  
 aaaaaaaaaa aaaaaaaaaa aa 2062

&lt;210&gt; 3

&lt;211&gt; 1050

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3



atgaccattg gagaaatgct acgatctttt ctcacaaaac tggagtgggt ttctaccttg 60  
 tttccaagaa ttccagttcc agttcaaaag aatattgatc aacagattaa aacccgacct 120  
 agaaaaatca agaaagatgg gaaggaaggt gctgaggaaa tagacagaca tgttgaacgc 180  
 agacgttcaa ggtctccaag gagatctctg agtccacgga ggtccccaag aaggtcaaga 240  
 agtagaagtc atcatcgga gggccatggg tcttctagtt ttgacagaga attagaaaga 300  
 gagaaagaac gccagcgact agagcgtgaa gccaaagaaa gggagaaaga acggcgaaga 360  
 tcccgaagta ttgaccgggg gttagaacgc aggcgcagca gaagtaggga aaggcataga 420  
 agtcgcagtc gaagtcgtga taggaaagg gatagaagg acagggatcg agaaagagag 480  
 aaagaaaatg agagaggtag aagacgagat cgtgactatg ataaggaaag aggaaatgaa 540  
 cgagaaaaag agagagagcg atcaagagaa aggtccaagg aacagagaag taggggagag 600  
 gtagaagaga agaaacataa agaagacaaa gatgataggc ggcacagaga tgacaaaaga 660  
 gattccaaga aagagaaaaa acacagtaga agcagaagca gagaaaggaa acacagaagt 720  
 aggagtcgaa gtagaatgc agggaaacga agtagaagta gaagcaaaga gaaatcaagt 780  
 aaacataaaa atgaaagtaa agaaaaatca aataaacgaa gtcgaagtgg cagtcaagga 840  
 agaactgaca gtgttgaaaa atcaaaaaaa cgggaacata gtcccagcaa agaaaaatct 900  
 agaaagcgta gtagaagcaa agaacgttcc cacaaacgag atcacagtga tagtaaggac 960  
 cagtcagaca aacatgatcg tcgaaggagc caaagtatag aacaagagag ccaagaaaaa 1020  
 cagcataaaa acaaagatga gactgtgtga 1050

<210> 4

<211> 25

<212> DNA

<213> Homo sapiens

<400> 4

cggcgaagat cccgaagtat tgacc

**Claims**

1. An isolated mammalian nucleic acid molecule selected from the group consisting of:
  - (a) Nucleic acid molecules encoding T128 polypeptide as shown in Figure 1, a polypeptide at least 80% identical to T128, or a fragment thereof, which is capable of cross-reacting with sera from patients with prostate cancer.
  - (b) Nucleic acid molecules comprising the nucleotide sequence depicted between nucleic acid residues 642 and 1688 of the sequence shown in Figure 2.
  - (c) Nucleic acid molecules, the complementary strand of which specifically hybridises to a nucleic acid molecule in (a) or (b).
  - (d) Nucleic acid molecules the sequence of which differs from the sequence of the nucleic acid molecule of (C) due to the degeneracy of the genetic code.
2. An isolated nucleic acid molecule according to claim 2, encoding the polypeptide sequence shown in Figure 1.
3. An isolated nucleic acid molecule which is at least 80% homologous to a nucleic acid sequence as defined in claim 1 or claim 2 and which encodes a polypeptide which is expressed in higher concentrations in cancerous tissue compared to that tissue when in a normal state.
4. An isolated nucleic acid molecule comprising at least 15 nucleic acids capable of specifically hybridising to a sequence within a nucleic acid molecule according to any preceding claim.
5. A vector comprising a nucleic acid molecule according to any preceding claim.

6. A host cell comprising a vector according to claim 5.
7. An isolated protein comprising an amino acid sequence encoded by a nucleic acid molecule according to any preceding claim.
8. An isolated protein according to claim 7 which comprises the amino acid sequence shown in Figure 1.
9. A fragment or derivative of a polypeptide according to claim 7 or claim 8.
10. A monoclonal antibody capable of specifically binding to a polypeptide, fragment or derivative according to any one of claims 7 to 9.
11. The use of an isolated nucleic acid molecule comprising a sequence according to any one of claims 1 to 4 to detect or monitor cancer.
12. The use of a nucleic acid probe which is capable of specifically hybridising an isolated nucleic acid molecule according to any of claims 1 to 4.
13. A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising a sequence according to claims 1 to 4 in a sample from a patient.
14. A method of detecting or monitoring cancer comprising the use of a nucleic acid molecule or probe according to claim 11 or claim 12 in combination with a reverse transcription polymerase chain reaction (RT-PCR).
15. A method of detecting or monitoring cancer comprising detecting or monitoring elevated levels of a polypeptide according to any of claims 7 to 9.
16. A method according to claim 15 comprising the use of an antibody selective for a protein or peptide as defined in any of claims 7 to 9 to detect the protein or peptide.

17. A method according to claim 16 comprising the use of an Enzyme-linked Immunosorbant Assay (ELISA).
18. Use or method according to any one of claims 11 to 17, wherein the cancer is a gastro-intestinal cancer, kidney cancer or a prostate cancer.
19. A kit for use with a method according to any one of claims 13 to 18 comprising a nucleic acid, protein or peptide, or an antibody as defined in any one of claims 1 to 4 or 8 to 10.
20. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of nucleic acid molecule comprising a nucleic acid sequence according to any of claims 1 to 4 or a pharmaceutically effective fragment thereof.
21. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a nucleic acid molecule hybridisable under high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence according to any of claims 1 to 4 or a pharmaceutically effective fragment thereof.
22. A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a polypeptide as defined in any of claims 7 to 9 or a pharmaceutically effective fragment thereof.
23. A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of an antibody according to claim 11.
24. A method according to any one of claims 20 to 23, wherein the cancer is a gastro-intestinal cancer.

25. A vaccine comprising a nucleic acid molecule having a nucleic acid sequence as defined in any of claims 1 to 4 or a pharmaceutically effective fragment thereof and a pharmaceutically acceptable carrier.
26. A vaccine comprising a polypeptide according to any of claims 7 to 9 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.
27. A polypeptide according to claims 7 to 9 or a pharmaceutically effective fragment thereof, attached to a carrier protein.




Figure 1

MTIGEMLR SFLT KLEW FSTLFP RIPVPVQKNIDQQIKTRPRKI  
KKDGKEGAEEIDRHVERRRSRSPRRSLSPRRSPRRSRSSH  
REGHGSSSFDRELEREKERQRLEREAKEREKERRRSRSIDRG  
LERRRSRSRERHRSRSRSRDRKGDRRDRDREREKENERGRR  
RDRDYDKERGNEREKERERSRERSKEQSRERGEVEEKKHKED  
KDDRRHRDDKRDSKKEKKHSRSRSRERKHSRSRSRSRNAGKR  
SRSRSKEKSSKHKNESKEKSNKRSRSGSQGR TDSVEKSKKR  
EHSPSKEKSRKRSRSKERSHKRDHSDSKDQSDKHDRRRSQSI  
EQESQEKQHKNKDET V Stop



Figure 2

ACGCGGGGTTTCCAATTATTTGTTTCATTTATTTATTTTCTACATAACTAAATTAGAAACCTCACTGCTTCAT  
 GGCAGTTGGTTTGCTATTGCTTCCAGTTTATTAGGGCTTCATTTTATATTAGAGCTGTTAAAAGATAACCT  
 TTAGACAGGAATTATCTAAAGTAGACATTTTATATTAGAGCTGTTAAAAGATAACCTTTAGACAGGAATTAT  
 CTAAAGTAGATCATATGTAGCTAGGTTATGGTGCAAGGTGTATGATGTGTGCAAATATGTCCACAGAAATAA  
 ATACATAGTAGGTATGTGGAATGTAAATTTAAGTCAATCGTTCCGCATAGTTTAGAAATGTAAGGGGCTTTT  
 TCATATTGTTAACTGAGTGAGATCAGTTCCCTTTATGCCTGTGAGGCTGCAGGGTTTGTTCCTCACTTGCATG  
 CACACACTAAGCCCAAATATTTCTGTTTCATTTCATTGTCAGATCAGGATATGAAAATAAAATTTTCTGTTAG  
 TTTTTTTTGTATTGAGATTCCAAAGATGGTAATATTTTATAATATTCATGTATATATGGAAATACTTTTTT  
 TGACGGCTAGGGTATCTTTTGTGTTTCTGTAGGACCTAGATGTGAAGGCTGGTGGAGGCTGTGTA  
ATGACCATTGGAGAAATGCTACGATCTTTTCTCACAAAACCTGGAGTGGTTTTCTACCTTGTTTTCCAAGAATT  
 CCAGTTCCAGTTCAAAGAATATTGATCAACAGATTTAAACCCGACCTAGAAAAATCAAGAAAGATGGGAAG  
 GAAGGTGCTGAGGAAATAGACAGACATGTTGAACGCAGACGTTCAAGGTCTCCAAGGAGATCTCTGAGTCCA  
 CGGAGGTCCCCAAGAAGGTCAAGAAGTAGAAGTCATCATCGGGAGGGCCATGGGTCTTCTAGTTTTGACAGA  
 GAATTAGAAAGAGAGAAAGAACGCCAGCGACTAGAGCGTGAAGCCAAAGAAAGGGAGAAAGAA  
CGGCGAAGATCCCGAAGTATTGACCGGGGGTTAGAACGCAGGCGCAGCAGAAGTAGGGAAAGGCATAGAAGT  
 CGCAGTCGAAGTCGTGATAGGAAAGGGGATAGAAGGGACAGGGATCGAGAAAGAGAGAAAAGAAAATGAGAGA  
 GGTAGAAGACGAGATCGTGACTATGATAAGGAAAGAGGAAATGAACGAGAAAAAGAGAGAGAGCGATCAAGA  
 GAAAGGTCCAAGGAACAGAGAAGTAGGGGAGAGGTAGAAGAGAAGAAACATAAAGAAGACAAAGATGATAGG  
 CGGCACAGAGATGACAAAAGAGATTCCAAGAAAGAGAAAAACACAGTAGAAGCAGAAGCAGAGAAAGGAAA  
 CACAGAAGTAGGAGTCGAAGTAGAAATGCAGGGAAACGAAGTAGAAGTAGAAGCAAAGAGAAATCAAGTAAA  
 CATAAAAATGAAAGTAAAGAAAAATCAAATAAACGAAGTCGAAGTGGCAGTCAAGGAAGAACTGACAGTGTT  
 GAAAAATCAAAAAACGGGAACATAGTCCCAGCAAAGAAAAATCTAGAAAGCGTAGTAGAAGCAAAGAACGT  
 TCCCACAAACGAGATCACAGTGATAGTAAGGACCAGTCAGACAAACATGATCGTCTGAAGGAGCCAAAGTATA  
 GAACAAGAGAGCCAAGAAAAACAGCATAAAAACAAAGATGAGACTGTG  
TGAAAATATTTTGTAAAAGTGGATCACATTGAATCCTATAAATGATTAAATCTGCTTTTTTCCCCACGTTG  
 AGATTGTGCAGTAGTTTCGCACTCCTCAAGCTCTCCCTGTAGGCTGCATTTTCATTTCTCTTCGTGTAGGG  
 AAGTGCCTTTGTAATTCATTTATTGCATTGGTGTTCACCCAATTGTTAAGTTTGATACATGATGCACAG  
 ATTGTTCTTGCAATTTTTATTGTTTGTGTTTTGAAATGTACAGTCTGTACATATGTCTGAAAATGTTTTAATT  
 CCTTTGGCATGGTTACCATGTTGGTTAAATTTGTATAAGGCAATAAACTGCCACTAATCCNAAAAAAAAAAAA  
 AAAAAAAAAAAAAA

Start codon (ATG) and stop codon (TGA) underlined





FIGURE 3




FIGURE 4

